Interview with Tim Oldham, CEO of AdAlta (ASX:1AD)

August 7, 2020

video

We talked with Dr. Tim Oldham about the prospects of AdAlta’s lead compound AD-214 as it enters the clinic for its first Phase 1 study, as well as the power of AdAlta’s i-body drug discovery platform.